New Jersey Bioscience Center Tenants

BC 1 Tenants

Merial Limited
75,000 square feet

Merial Limited, a Boehringer Ingelheim company, is dedicated to the discovery, development, manufacture and delivery of innovative pharmaceuticals and vaccines for all animal species. It occupies a self-standing 60,000-square-foot building as its North American pharmaceutical R&D headquarters.

BC 2 Tenants

Allergan Plc
32,000 square feet

Allergan plc (NYSE:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company. Allegan United States: March 17, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team.

Ascendia Pharmaceuticals LLC


Ascendia is a speciality pharmaceutical company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for pre-clinical and clinical stage drug candidates.  Ascendia specializes in creating formulations for poorly-water soluble molecules using nano-particle technologies.  Ascendia assesses the feasibility of a broad array of formulation options in order to improve a drug’s bioavailability. Ascendia’s technologies include nano-emulsions, amorphous solid dispersions, and production of nano-crystals.  Ascendia provides development and testing services - from discovery-stage molecules to life-cycle-management projects - creating formulation solutions with enhanced biopharmaceutical properties suitable for clinical scale-up. 

BC 3 Tenants

Hurel Corporation 
5,000 square feet

Hurel Corporation provides patented micro fluidic devices and cell culture that elevate the metabolic competency and endurance of cells cultured in vitro, and that simulate pharmacokinetic interactions among multiple tissues and organs. These proprietary capabilities produce unrivaled levels of physiologically relevant predictive sensitivity- “human relevance”- that define the current state of the art of hepatic and multi-tissue cell-based assays.

7,000 square feet

Orthobond uses proprietary non-polymer technology developed at Princeton University to enhance the surface characteristics of medical grade substrates. This unique attachment chemistry can be customized to provide medical companies with surfaces that improve the performance of their metallic and polymeric implants, instruments and ancillary components. Orthobond is currently focused on using this technology to create antimicrobial surfaces that may help to reduce the risk of infection associated with medical implants. Other applications include, but are not limited to, improving adhesion between surfaces, making surfaces hydrophobic or hydrophilic, or attaching specific molecules such as proteins, peptides and/or small molecules to a surface.

Rutgers Technology Center II
26,000 square feet

Rutgers Technology Center II is a 26,000-square-foot facility that will house advanced development laboratories where university researchers will collaborate with technical experts in startup ventures, established corporations and government agencies. Together they will define new capabilities for wireless computer and cell phone networks, invent lightweight yet powerful energy sources for products ranging from body implants to hybrid cars, and formulate targeted drug therapies to relieve chronic diseases. Tenants of the Rutgers Technology Center II include:


WINLAB (Wireless Information Network Laboratory) is an industry-university cooperative research center focused on wireless technology. WINLAB was founded at Rutgers University in 1989. Its research mission is to advance the development of wireless networking technology by combining the resources of government, industry and academia. The center's educational mission is to train the next generation of wireless technologies via graduate research programs that are especially relevant to industry.

Energy Storage Research Group

Energy Storage Research Group (ESRG) is a technically diverse applied research group of faculty, research staff, graduate, and undergraduate students whose charter is the research, development and advancement of the new energy storage device chemistries enabled by advancements in materials science. The group focuses on a wide range of nonaqueous and solid state chemistries, the majority of which incorporating ESRG developed nanocomposites which enable significant new abilities to deliver and store large amounts of power and energy per weight of device. The group focuses not only on the development of new materials but especially on the in-depth understanding of bulk and interfacial operational and failure mechanisms which occur on the nanoscale during the operation of these ionically active materials. The ESRG maintains over 3000 square feet of off campus laboratories dedicated to this mission. Capabilities range from fabrication and broad characterization of macro and nanoelectrode materials to the development of rechargeable energy storage devices of flat laminar design incorporating these materials to evaluate electrochemical performance.


Incubator at North Brunswick

The Incubator at North Brunswick is one of the more significant incubation facilities in the nation dedicated to life sciences and biotechnology companies - a 46,000 sq. ft. biotech incubator in a 50-acre research park in North Brunswick in the heart of New Jersey's "Research Corridor." 

Click here for a list of tenants at the Incubator at North Brunswick.

BC 4 Tenants

Chromocell Corporation
26,000 square feet

Chromocell is a life sciences company commercializing a novel technology that allows the rapid and automated production of stable cell lines expressing or suppressing multiple genes, which in turn enables the production of powerful cell-based assays and products for use in drug screening and development.

Step-Out-Labs at North Brunswick 

The Step Out Labs at North Brunswick offers 32,646 sq.ft. of affordable lab and office space that is “plug-and-play” ready. The Step out labs are strategically designed with shared common areas and abundant amenities to create a first-class life sciences environment where post incubation tenants can focus on core scientific activities rather than administrative and facility functions.

Tenants of the Step Out Labs include:

Adlai Nortye US

Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs in the field of oncology/immuno-oncology. The company's mission is to improve patient lives by developing differentiated, innovative medicines that help people live better and longer.

Apicore LLC
Apicore, LLC provides process R&D and API manufacturing services for the pharmaceutical industry worldwide. Its products and services range from APIs for the generic industry to custom synthesis for early phase pharmaceutical research and branded products.

Bionex Pharmaceuticals

Bionex’s mission is to realize bio-pharmaceutical and life sciences into commercial products and services that benefit human health. Strategically, Bionex engages in two areas of business activities. First, Bionex offers contract R&D services, from early-stage concept development to full-scale commercialization, in bio-pharmaceutical, food and cosmetic products. Second, Bionex develops and out-licenses its own proprietary formulations, technologies, and products related to drug, health food, and skin-care applications.

Genomic Prediction Inc.

Genomic Prediction offers state-of-the-art preimplantation genetic testing services including amplification products, and testing for aneuploidy, single gene disorders and polygenic disorders.

Grace Therapeutics LLC


Grace Therapeutics LLC is a start-up life science company. Their goal is to develop improved formulations of select approved drugs including combination drugs for existing and/or additional therapeutic indications. They also intend to develop innovative drug delivery systems that improve the clinical outcome of currently marketed products. Their management team and network of consultant experts are experienced at founding and growing companies from the earliest stages of development through product approval and commercialization.

Kamat Pharmatech, LLC

Kamat Pharmatech, LLC is a company that operates as a contract development organization providing leadership in formulation development, process development, technology transfer, manufacture and regulatory support while developing a portfolio of unique generic injectable and topical products.